CM, expanding its market reach. JP Morgan upgrades the stock, projecting strong sales and a multi-billion opportunity.

Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

Amvuttra is now approved in the US to treat both cardiomyopathy and polyneuropathy manifestations of ATTR amyloidosis.

This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with ...

Alnylam Pharmaceuticals’ Amvuttra (vutrisiran) has been approved by the Food and Drug Administration (FDA) to treat ...

The U.S. Food and Drug Administration (FDA) has approved a new drug for a serious heart condition that affects thousands of ...

Alnylam Pharmaceuticals gains FDA approval for Amvuttra in ATTR-CM, boosting revenue prospects. Click here to read an ...

Along with tafamidis and acoramidis, the drug is now the third for ATTR-CM, but it comes with a whopping price tag of ...

Alnylam's Amvuttra enters ATTR-CM drug race, and Expedition Therapeutics seeks to bring Chinese drugs to the U.S.

Alnylam announced the FDA approval of its supplemental new drug application for vutrisiran, an RNA interfering small molecule ...